Naratriptan: a review

Bibliography

• HAMEL E, FAN E, LINVILLE D, TING V, VILLEMURE J, CHIA: Expression of mRNA for the serotonin 5-hydroxytryptaminem/B receptor subtype in human and bovine cerebral arteries. Mol Pharmacol. (1993) 44:242–246.
   PubMed Web of Science ®Google Scholar
• CONNOR HE, BEATTIE DT: 5-HT receptor subtypes and migraine. In: Migraine: Pharmacology and Genetics. San-dler M, Ferrari M, Harnett S (Eds.), Chapman & Hall London, UK (1996):18–31.
   Google Scholar
• BUZZI MG, MOSKOWITZ MA: The antimigraine drug su-matriptan (GR43175) selectively blocks neurogenic Plasma extravasation from blood vessels in dura ma-ter. Br. J. Pharmacol. (1990) 99:202–206.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ MA: Neurogenic versus vascular mecha-nisms of sumatriptan and ergotalkaloids in migraine. Trends Pharmacol. Sci. (1992) 13:307–312
   PubMed Web of Science ®Google Scholar
• HUMPHREY PPA, GOADSBY PJ: The mode of action of sumatriptan is vascular? A debate. Cephalalgia (1994) 14:401–410.
   PubMed Web of Science ®Google Scholar
• CONNOR HE, O'SHAUGHNESSY CT, FENIUK W et al:,GR85548: a potent, selective agonist for the intracra-nial vascular 5HT1 receptor. Br. J. Pharmacol. (1993) 108:99P.
   Google Scholar
• PERREN MJ, CONNOR HE, FENIUK W, NORTH PC, SAYNOR DA, HUMPHREY PPA: Pharmacological activity in vivo of GR85548 a selective 5HT1 receptor agonist. Br. J. Pharmacol. (1993) 108:260P.
   Web of Science ®Google Scholar
• CONNOR HE, FENIUK W, BEATTIE DT et al.: Naratriptan biological profile in animal models relevant to mi-graine. Cephalalgia (1997) 17:143–147.
   Web of Science ®Google Scholar
• WAINSCOTT DB, JOHNSON KW, PHEBUS LA, SCHAUS JM, NELSON DL: Human 5-HT1F receptor-stimulate [35S] GTP gammas binding: Correlation with inhibition of guinea pig dural plasma protein extravasation. Euro. J. Pharmacol. (1998) 352(1):117–124.
   PubMed Web of Science ®Google Scholar
• NEWMAN-TAUCREDI A, CONTE C et al.: Agonist activity of anti-migraine drugs at recombinant human 5-HT1 A receptors: Potential implication for prophylactic and acute therapy. Naunyn Schmiedebergs. Arch. Pharmacol (1997) 355(6)682–688.
   Google Scholar
• CERAVOLO K: Effect of subcutaneous naratriptan ad-ministration on cerebral blood flow in migraine pa-tients. A H2150 PER study. The Annual Meeting of the American Academy of Neurology (1999).
   Google Scholar
• YOGENDRAN L, BOSWELL D, NACCI P, WINTER P: Effect of subcutaneous naratriptan on forearm blood flow. Cephalalgia (1998) 18(7):476–480.
   PubMed Web of Science ®Google Scholar
• MAASSEN VANDENBRINK A, REEKERS M, BAX WA, FER-RARI MD, SAXENE PR: Coronary side-effects potential of current and prospective anti-migraine drugs. Circula-tion (1998) 98:25–30.
   PubMed Web of Science ®Google Scholar
• SOMERS G: Glaxo Wellcome files (Unpublished data).
   Google Scholar
• SKINGLE M, BIRCH PJ, LEIGHTON GE, HUMPHREY PPA: Lack of antinociceptive activity of sumatriptan in ro-dents. Cephalalgia (1990) 10:207–212.
   PubMed Web of Science ®Google Scholar
• GOADSBY P, KNIGHT YE: Naratriptan inhibits trigemi-nal neurons after intravenous administration through an action at the serotonin (5-11T1B/1D) receptors. Br. J. Pharmacol. (1997) 122:918–922.
   PubMed Web of Science ®Google Scholar
• MATHEW NT, ASGHARNEJAD M, PEYKAMIAU M, LAU-RENZA A: Naratriptan is effective and well tolerated in the acute treatment of migraine. Neurology (1997) 49:1585–1490.
   Google Scholar
• KLASSAN A, EKLIND A, ASGHARNEJAD M, WEBSTER C,LAURENZA A: Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 study group. Headache (1997) 37:640–645.
   Google Scholar
• BOMHOF MA, KEYWOOD J, PRAVALIER A, ENAHORD H,WINTER P, HASSAWI H: Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan long-term study group. Cephalal-gia (1998) 18:33–37.
   PubMed Web of Science ®Google Scholar
• JONES M, SALONEN R, KANE K, THAVENTHIRAN L, SAIERS J: Naratriptan tablets 2.5 mg are particularly ef-fective and well tolerated in non-severe migraine at-tacks. Data from a one year, open label study. Neurology (1999) 52 (Supp1.2):A207–A208.
   Google Scholar
• SALONEN R, KANE K, THAVENTHIRAN L: Naratriptan tablets 2.5 mg are effective, long-acting and well- in triptan naive patients. Neurology (1999) 52 (Supp1.2):A207.
   Google Scholar
• O'QUINN S, JONES M, KANE K, THAVENTHIRAN L, SAIERS J: Naratriptan tablet 2.5 mg exhibit prolonged action and are well-tolerated in non-serve migraine attacks: Data from comparative study with sumatriptan. Neu-rology (1999) 52 (Supp1.2):A256–257.
   Google Scholar
• STARK S, O'QUINN S, MCNEAL S, PAIT, G, WATSON C: Naratriptan is effective for the treatment of migraine headache in sumatriptan non-responders. Neurology (1999) 52 (Supp1.2):A207.
   Google Scholar
• SCHOENEN J, JONES MARTIN, KANE R, VANASSCHE P, SAUERS J: Naratriptan 2.5 mg tablets have similar effi-cacy in the acute treatment of migraine as zolmitriptan 2.5 mg tablets, but exhibit a longer duration of action and are better tolerated: results of a comparative study. Neurology (1999) 52 (Supp1.2):A257.
   Google Scholar
• GOADSBY PJ, WINNER PD, ASGHARNEJAD M: Twenty-four hour maintenance of headache relief after treat-ment of migraine with naratriptan tablets: A review of data from controlled clinical trials. The meeting of the European Headache Federation. Corfu, Greece (1998).
   Google Scholar
• DAHLOF C: Naratriptan injection compared with su-matriptan injection. Glaxo Wellcome files. Quoted in ref. 25.
   Google Scholar
• WINTER PD, ASGHARNEJAD M: Tolerabiliy of naratrip-tan tablets: a review. 3rd Congress of Europiean Headache Federation. Corfu, Greece (1998). T Mathew Headache Clinic, 1213 Hermann Drive, STE 350, Houston, Texas 77004, USA.: +1 713 528 1916; Fax: +1 713 526 6369;
   Google Scholar